3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Capecitabine
13
Fluorouracil
11
Oxaliplatin
10
Bevacizumab
9
Leucovorin
6
Irinotecan
6
HMPL-013
4
Folfox protocol
4
Cetuximab
4
ferric carboxymaltose
3
regorafenib
2
gadolinium ethoxybenzyl DTPA
2
gadobenic acid
2
Triamcinolone
2
Standard of Care
2
Radiofrequency Ablation
2
Pirinitramide
2
Morphine
2
Esomeprazole
2
Analgesia, Epidural
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
sodium phosphate
1
raltitrexed
1
polyethylene glycol 3350
1
iron isomaltoside 1000
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
gadoteridol
1
gadoterate meglumine
1
gadodiamide
1
gadobutrol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Colorectal Neoplasms
×
gadodiamide
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled